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Background: Ophthalmic antibiotic therapy in large animals is often used empirically because of the lack of
pharmacokinetics studies. The purpose of the study was to determine the pharmacokinetics of topical tobramycin
0.3% ophthalmic solution in the tears of normal horses using an automated immunoassay analysis.
Results: The mean tobramycin concentrations in the tears at 5, 10, 15, 30 minutes and 1, 2, 4, 6 hours after
administration were 759 (±414), 489 (±237), 346 (±227), 147 (±264), 27.6 (±28.4), 14.8 (±66.6), 6.7 (±18.6), and 23.4
(±73.4) mg/L. Mean tobramycin concentration was maintained above the MIC90 for commonly isolated bacteria for
68.5 min.
Conclusion: A single dose of topical tobramycin resulted in therapeutic concentrations of tobramycin in the tears
for 1 h after administration. Therapeutic levels of tobramycin remained in equine tears 6 times longer than was
reported in rabbit tears.
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Ulcerative keratitis commonly occurs in horses. Their
prominent eye profile and active nature likely predispose
them to ocular trauma [1]. Breaks in the corneal surface
allow commensal conjunctival and corneal organisms to
colonize the epithelium or the stroma. Primary corneal
bacterial pathogens, such as Pseudomonas, can establish
infection despite an intact corneal epithelium [1-3]. Bac-
teria most frequently cultured from the corneas of
horses with ulcerative keratitis include Streptococcus
equi subspecies zooepidemicus, Pseudomonas aeruginosa,
and Staphylococcus spp. [2,4,5].
Although general recommendations are to use a
broad-spectrum initial antimicrobial therapy for ulcera-
tive keratitis, the antibiotic choice and frequency of ad-
ministration are empirical and guided by the clinical
examination and cytological evaluation of corneal swabs
[1]. Therapy is modified based on bacterial and fungal
culture and sensitivities, when they become available in
the following days to weeks [1,6].* Correspondence: rleguill@ucalgary.ca
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distribution, and reproduction in any mediumAppropriate antimicrobials to prevent infection in-
clude triple antibiotic ointment (neomycin, polymyxin B,
bacitracin), tetracyclines, and aminoglycosides [1,2].
Fluoroquinolones are often used to treat established
infections [1]. Treatment intervals for ulcerative keratitis
range from q.6 h to q.8 h for prophylaxis of infection,
and may be as frequent as q.2 h to q.4 h for corneas that
are infected [1].
Tobramycin is commonly used to treat bacterial kera-
titis in horses. It is an aminoglycoside antibiotic with a
mainly gram negative spectrum of activity. It is bacteri-
cidal, inhibiting protein synthesis through irreversible
binding to the 30S and 50S ribosomal subunits [7]. To
the authors’ knowledge, the pharmacokinetics of topical
ophthalmic gentamicin and tobramycin has only been
studied in humans and rabbits while the pharmacokinet-
ics of ciprofloxacin has also been studied in horses and
dogs [8-11]. In a rabbit study, tobramycin and ofloxacin
concentrations were above the MIC90 for gram positive
and gram negative organisms for 10 and 240 minutes, re-
spectively, after drug administration, whereas gentamicin
concentrations were above the MIC90 for 20 minutes for
gram positive organisms and 120 minutes for gram nega-
tive organisms [10,12]. Another study done on humans
found that after repeated administration, tobramycin andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Figure 1 Validation of the tobramycin immunoassay on tear
samples: Recovery of tear tobramycin from Schirmer test strips was
assessed at four concentrations within the linear range of the
immunoassay (0.5 – 10 mg/L) and compared to direct assay of
dilute tobramycin solutions. The average recovery was 96.5%. Assays
were performed in duplicated and least squares linear regression
was used to derive the lines of best fit.
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5 species of bacteria for 251 and 605 minutes respectively
[11]. The pharmacokinetics of topical ophthalmic cipro-
floxacin has been evaluated in the tears of normal horses
and dogs. The ciprofloxacin concentrations remained
above the MIC90 for 6 hours after administration in both
species [8,9]. In all studies the antibiotic concentrations
rapidly declined following administration [8-11].
Because tobramycin is frequently used empirically for
the treatment of ocular disease in the horse, the object-
ive of this study is to determine the pharmacokinetics of
tobramycin in normal horses’ tears. We have measured
the concentration of tobramycin in equine tears at vary-
ing time intervals following topical application.
Materials and methods
The study was approved by the University of Calgary Vet-
erinary Sciences Animal Care Committee. Ten healthy,
mixed breed horses with normal ophthalmic examina-
tions (including Schirmer tear test, slit-lamp biomicro-
scopy, indirect ophthalmoscopy, and fluorescein test)
were used. There were 5 geldings and 5 mares, ranging in
age from 1 to about 20 years old. Horses were housed in
stalls for 24 hours prior to testing to prevent exposure to
sun, wind, and dust.
Horses were sedated with xylazine intravenously (0.3
to 0.45 mg/ kg) to facilitate administration of the tob-
ramycin. One fractious horse received butorphanol
(0.02 mg/kg) in addition to xylazine prior to the admin-
istration of tobramycin. A 1 mL syringe and metal can-
nula was used to deliver 100 μL of 0.3% tobramycin
(TobrexW, Alcon Laboratories Inc., Fort Worth, TX,
USA) into the ventral cul-de-sac of each eye on day 0.
Tear samples were obtained by placing a pre-weighed
Schirmer tear test strip in the ventral cul-de-sac of the
eye for 30 seconds at 5, 10, 15, 30 minutes or 1, 2, 4,
6 hours after tobramycin administration. After tear col-
lection the test strips were immediately weighed to de-
termine the fluid weight collected and then stored in
sealed 3 ml plastic tubes at −70°C until analysis. Tear
volume in microliters was equated to tear weight in
milligrams. To increase the number of samples per time
point, both the left and right eyes of the 10 animals were
treated on day 0, then once again after a seven day
washout period. The sample times for the total 40 eyes
were randomized, yielding 5 samples for each of the 8
time periods.
Tobramycin concentrations were determined by im-
munoassay. Schirmer test strips were extracted with
200 μl of drug-free human serum (Bio-Rad Laboratories
Ltd, Mississauga, ON, Canada) for 10 minutes. The
paper was mechanically pulped and then centrifuged at
10,000 g for 10 minutes. Supernatant fluid was analyzed
on a Cobas C601 automated chemistry analyzer (RocheDiagnostics, Laval, Canada) using the manufacturer’s
calibrators and serum tobramycin method at Foothills
Medical Center, Calgary, AB, Canada. Evaluation of the
extraction efficiency, precision and limit of detection for
tear tobramycin from Schirmer test strips is described.
Tobramycin concentration in the tears is expressed as
mean ± SD. Pharmacokinetic analysis was performed




A tobramycin immunoassay developed for use on human
serum was adapted for use with tear fluid collected on
Schirmer test strips. In human serum, the assay perform-
ance specification was confirmed to be linear from 0.5 to
10 mg/L with within–day coefficients of variation of 3.6%
at 1.7 mg/L and 3.5% at 7.8 mg/L (n = 10). The thera-
peutic TobrexW (Alcon Laboratories Inc., Fort Worth,
TX, USA) 0.3% solution (3000 mg/L) was diluted and
assessed by immunoassay to be 3167 mg/L, 105.5% of the
stated concentration. Dilute aqueous tobramycin solu-
tions were applied to Schirmer test strips in 5–40 μl ali-
quots and extracted into drug-free human serum prior to
tobramycin immunoassay to assess the linearity and re-
covery of the antibiotic (Figure 1). The extraction method
recovered 96.5% of tobramycin from the Schirmer test
strips (Figure 1). The within-day coefficient of variation
to tear extraction from the Schirmer test strips was deter-
mined to be 6.5% at 0.86 mg/L and 1.7% at 6.8 mg/L
(n = 8) while analyzing 20 μL samples (Figure 1). The
limit of detection was estimated to be 0.06 mg/L in 20 μL
samples.
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The mean volume of tear fluid determined gravimetrically
was 19 μL per Schirmer strip and tear volumes ranged
from 4 to 37 μL. Tobramycin levels were determined in
the drug-free human serum used to extract the Schirmer
strips and the amount of tobramycin was expressed per
volume of tear fluid to determine the tear drug concentra-
tion at each time point. The mean tobramycin concentra-
tions at 5, 10, 15, and 30 minutes after administration
were 759 (± 414), 489 (± 237), 346 (± 227), 147 (± 264)
mg/L (Figure 2). The mean tobramycin concentration
at 1, 2, 4, and 6 hours after administration were 27.6
(± 28.4), 14.8 (± 66.6), 6.7 (± 18.6), and 23.4 (± 73.4) mg/L
(Figure 2).
Pharmacokinetics
The initial concentration of the tobramycin at time 0
was calculated to be 905 mg/L and mean concentration
declined to 16 mg/L (MIC90) by 68.5 min. The elimin-
ation rate constant in the first 60 minutes was
0.059 min-1 associated with a half-life of 11.7 minutes.
Discussion
The results of this study are consistent with other tear
film studies conducted in humans, horses and rabbits.
We found that the concentration of drug in the tear film
rapidly declined exponentially in the first 50 minutes,
linear on logarithmic axes, and then plateaued and be-
came variable as the limit of detection for the drug assay
was approached. After one hour, the low tear drug levels
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Figure 2 Pharmacokinetics of tobramycin ophthalmic solution
in horses’ tears: The geometric mean concentration of tobramycin in
tears was determined over 6 h (n= 5 at time points 5, 10, 15, 30 min
and 1, 2, 4 and 6 h) after single topical administration of 0.3%
tobramycin ophthalmic solution. Tobramycin concentrations were log
transformed to derive the mean and standard deviation. Bars represent
mean± SD. Horizontal dashed lines are shown for the concentration of
tobramycin in the ophthalmic solution, 3000 mg/L and the MIC90 of
16 mg/Lin horses, dogs, and rabbits, showed a large amount of
variation of tear antimicrobial concentrations [8-10].
The authors suggested that this variation may be
explained by inter-animal variation and low sample
numbers [8,9]. Similar to these studies, we also had one
sample in each the 5 min, 2 hr, 4 hr and 6 hr groups that
were below the limit of quantification. The previous
studies hypothesized that this occurred from not fully
extracting the drug from the strips, from errors in the
amount of drug in the syringe because of air, and from
loss from blinking after the drop was given [8,9]. In the
previous studies the animal’s other eye was normal, but
in our study the 4 hr and 6 hr samples were from the
same horse [8,9]. This is suggestive of sensitivity to the
drug resulting in increased tearing.
We showed that the mean tobramycin in the tear film
reached the MIC90 of 16 mg/L after 68.5 minutes, indi-
cating that therapeutic concentrations of the drug were
maintained for over an hour, compared to the 10 minutes
reported in the rabbit tears [10]. Our result of an initial
concentration of 905 mg/L of tobramycin at time 0 is in
agreement with the estimates from a previous study on
tear volume in horses [13]. In addition, when our results
are compared to the same study, tear production is likely
the main factor involved in tobramycin clearance from
the surface of the eye [13]. The horses used in the study
were normal, however it would be expected that tobra-
mycin levels in the tear film of a horse with a corneal
ulcer would decrease more quickly than a normal horse,
as corneal ulceration causes increased tear production.
Tear production is also impacted by drugs, including
sedatives and general anesthetics. A study in dogs found
that sedation with xylazine alone did not impact tear
production, butorphanol caused a mild decrease in tear
production, while the combination of the two drugs sig-
nificantly decreased tear production [14]. Another study
showed that in horses intravenous xylazine did not affect
tear production, while general anesthesia with halothane
caused a decrease in tear production [15]. This suggests
that the xylazine used for sedation in the study did not
impact the tear production. It is possible that the com-
bination of xylazine and butorphanol used in the frac-
tious horse caused decreased tear production, and
subsequent elevated concentrations of tobramycin in the
tear film. When the individual measurements from this
horse were examined, the concentrations were in the
middle of the range compared to the other horses in the
group. This suggests that it is unlikely that the sedation
had a significant effect.
The MIC90 for gram positive and gram negative ocular
isolates from humans has previously been reported as
16 mg/L for tobramycin [12], but there is limited pub-
lished data regarding the aminoglycoside susceptibilities
for bacteria isolated from horses [16,17]. For equine
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centration methods for tobramycin, susceptibility criteria
were <4 mg/L for susceptible, 8 mg/L for moderately sus-
ceptible, and >16 mg/L for resistant isolates [18].
Treatment of bacterial infections requires therapeutic
levels of antimicrobials within the tissues. Maintaining
therapeutic concentrations of drug could be achieved by
improving drug retention in the tears, by using higher
concentrations of the drug, and by more frequent drug ad-
ministration [19,20]. In this sense, a study in rabbits found
higher concentrations of tobramycin in the tears and
within the ocular tissues when the drug was combined
with xanthan gum in a product called TobraDex STW
(Alcon Laboratories Inc., Fort Worth, TX, USA) versus
tobramycin alone [20]. Exposure to the tear pH causes the
ionic bond between the xanthan gum and drug molecules
to break, increasing the viscosity of the drop when it is
within the tear film, thus prolonging the retention of the
drug in the tears [20]. This study found that tear tobra-
mycin concentration was 8 and 12.5 times higher in the
formulation using xanthan gum 10 and 60 minutes after
topical application respectively [20]. Interestingly, increas-
ing retention in the tears did not affect the aqueous
humour concentrations of the drugs [20].
Using higher drug concentrations is another way to
achieve therapeutic levels within infected tissues. A
study in rabbits demonstrated that tear and corneal
tobramycin levels increased proportionally with the con-
centration of drug administered [19]. Tobramycin was
not detected in the cornea or aqueous 15 minutes fol-
lowing application of a 0.3% solution and concentrations
greater than 1.1% were required to achieve penetration
into the aqueous. However, tobramycin concentrations
higher than 0.3% caused a significant decrease in the
rate of corneal healing following hourly drug application
[19]. Further, the use of 1.1% and 4.0% tobramycin solu-
tions administered hourly compared to 0.3% adminis-
tered every 15 minutes did not statistically reduce the
number of colony forming units (CFU) in Pseudomonas
aeruginosa keratitis in rats [19]. Interestingly, an in vitro
study showed that tobramycin affected the migration of
canine corneal epithelial cells less than all the other anti-
microbial agents tested, including ciprofloxacin [21].
This suggests that tobramycin has the least impact on
corneal wound healing, making it potentially more ad-
vantageous in the treatment of superficial corneal
ulcerations [21].
A recent study in horses examined the ocular penetra-
tion of ciprofloxacin and moxifloxacin through intact
corneal epithelium following topical application [22].
Therapeutic levels of both drugs were found in the tear
film and cornea, but similar to the tobramycin studies,
aqueous humor concentrations of moxifloxacin and
ciprofloxacin were low and undetectable, respectively[22]. Further research is needed to determine the pene-
tration of tobramycin into the ocular tissues.
In addition to pharmacokinetics considerations, the
development of antimicrobial resistance is a concern in
both human and veterinary ophthalmology. While a
study from Florida found that Pseudomonas aeruginosa
showed a statistically significant increase in resistance to
tobramycin over several years, other studies found that
100% of their cultures were susceptible to the drug [2,5].
In order to minimize the development of further anti-
microbial resistance, tobramycin should be used judi-
ciously or in combination with other antibiotics based
on pharmacokinetics studies in each species [2,23].
Conclusions
This study validated an extraction and immunoassay
method allowing the measurement of tobramycin in
equine tears. We are also describing for the first time the
pharmacokinetics of tobramycin ophthalmic solution in
horses. Pharmacokinetic information is vital to avoid em-
pirical use of antibiotics and development of bacterial re-
sistance. Further research is needed to determine the
penetration of tobramycin into equine ocular tissues in
order to aid in the development of therapeutic schedules.
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